Adaptimmune Therapeutics (ADAP) Short Interest Ratio & Short Volume $0.66 -0.01 (-1.48%) (As of 11/20/2024 ET) Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Adaptimmune Therapeutics Short Interest DataAdaptimmune Therapeutics (ADAP) has a short interest of 5.35 million shares. This marks a -3.78% decrease in short interest from the previous month. The short interest ratio (days to cover) is 4.5, indicating that it would take 4.5 days of the average trading volume of 1.73 million shares to cover all short positions.Current Short Interest5,350,000 sharesPrevious Short Interest5,560,000 sharesChange Vs. Previous Month-3.78%Dollar Volume Sold Short$3.88 millionShort Interest Ratio4.5 Days to CoverLast Record DateOctober 31, 2024Outstanding Shares255,880,000 sharesPercentage of Shares Shorted2.09%Today's Trading Volume4,158,925 sharesAverage Trading Volume1,733,154 sharesToday's Volume Vs. Average240% Short Selling Adaptimmune Therapeutics? Sign up to receive the latest short interest report for Adaptimmune Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartADAP Short Interest Over TimeADAP Days to Cover Over TimeADAP Percentage of Float Shorted Over Time Ad DTIWhen it comes to NVDA… “acceleration cycles” are the keyExpert options trader Graham Lindman has been working on a new way to tap into Nvidia’s options… By simply isolating outsized “acceleration cycles” within Nvidia stock (most investors don’t even know it exists)... And thanks to many months and late nights working out the kinks of the systems… They have finally found a way to target these cycles on Nvidia over and over again.Use this link to see Nvidia Unchained right away! Adaptimmune Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 10/31/20245,350,000 shares $3.88 million -3.8%N/A4.5 $0.73 10/15/20245,560,000 shares $4.89 million -8.7%N/A3.5 $0.88 9/30/20246,090,000 shares $5.79 million -13.0%N/A3.6 $0.95 9/15/20247,000,000 shares $7.77 million +2.5%N/A3.9 $1.11 8/31/20246,830,000 shares $8.67 million -4.2%N/A3.7 $1.27 8/15/20247,130,000 shares $7.77 million No ChangeN/A3.3 $1.09 Get the Latest News and Ratings for ADAP and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Adaptimmune Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 7/31/20247,130,000 shares $9.48 million +13.2%N/A3.5 $1.33 7/15/20246,300,000 shares $7.84 million +11.7%N/A4 $1.25 6/30/20245,640,000 shares $5.50 million +15.1%N/A3.6 $0.97 6/15/20244,900,000 shares $4.95 million +6.1%N/A3.3 $1.01 5/31/20244,620,000 shares $5.22 million +34.3%N/A2.8 $1.13 5/15/20243,440,000 shares $4.27 million -2.3%N/A2.5 $1.24 4/30/20243,520,000 shares $4.19 million +3.2%N/A2.3 $1.19 4/15/20243,410,000 shares $3.58 million +6.6%N/A1.7 $1.05 3/31/20243,200,000 shares $5.06 million +2.9%N/A1.7 $1.58 3/15/20243,110,000 shares $4.60 million +11.1%N/A1.7 $1.48 2/29/20242,800,000 shares $4.40 million -4.4%N/A1.6 $1.57 2/15/20242,930,000 shares $3.66 million -37.8%N/A2.1 $1.25 1/31/20244,710,000 shares $4.52 million -18.4%N/A3.8 $0.96 1/15/20245,770,000 shares $4.75 million +1.2%N/A9.3 $0.82 12/31/20235,700,000 shares $4.52 million -6.9%N/A9.6 $0.79 12/15/20236,120,000 shares $2.75 million -0.8%N/A12 $0.45 11/30/20236,170,000 shares $3.09 million +3.0%N/A14.4 $0.50 11/15/20235,990,000 shares $3.00 million +2.4%N/A14.3 $0.50 10/31/20235,850,000 shares $3.16 million -12.6%N/A14.2 $0.54 10/15/20236,690,000 shares $4.39 million +12.1%N/A14.7 $0.66 9/30/20235,970,000 shares $4.66 million -1.3%N/A12.2 $0.78 9/15/20236,050,000 shares $4.91 million +3.1%N/A10.3 $0.81 8/31/20235,870,000 shares $4.58 million +1.9%N/A8.3 $0.78 8/15/20235,760,000 shares $4.49 million +0.4%N/A6.5 $0.78 7/31/20235,740,000 shares $5.41 million +1.4%3.9%6.5 $0.94 7/15/20235,660,000 shares $5.10 million -5.5%3.8%6.2 $0.90 6/30/20235,990,000 shares $5.54 million -19.6%4.1%6.3 $0.93 6/15/20237,450,000 shares $7.52 million -25.2%5.1%8.4 $1.01 5/31/20239,960,000 shares $10.16 million +8.7%6.8%11.6 $1.02 5/15/20239,160,000 shares $12.73 million +2.0%6.2%12.1 $1.39 4/30/20238,980,000 shares $12.75 million +19.9%6.2%12.5 $1.42 4/15/20237,490,000 shares $10.19 million +11.3%5.1%11.6 $1.36 3/31/20236,730,000 shares $7.34 million +28.7%4.6%11.9 $1.09 3/15/20235,230,000 shares $5.91 million +81.0%3.6%9.6 $1.13Blackrock’s Sending THIS Crypto Higher on Purpose (Ad)It's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…YES, I WANT THE #1 CRYPTO NOW 2/28/20232,890,000 shares $5.12 million +1.8%2.0%6.5 $1.77 2/15/20232,840,000 shares $4.69 million +1.4%2.0%8.4 $1.65 1/31/20232,800,000 shares $5.24 million +3.3%1.9%6.4 $1.87 1/15/20232,710,000 shares $5.07 million -8.1%1.9%5.1 $1.87 12/30/20222,950,000 shares $4.31 million +7.7%2.0%5.6 $1.46 12/15/20222,740,000 shares $3.73 million -1.4%1.9%5.3 $1.36 11/30/20222,780,000 shares $6.03 million -26.1%1.9%5.3 $2.17 11/15/20223,760,000 shares $8.95 million +12.6%2.6%7.6 $2.38 10/31/20223,340,000 shares $4.74 million -10.0%2.3%7.9 $1.42 10/15/20223,710,000 shares $4.19 million -6.6%2.6%9.3 $1.13 9/30/20223,970,000 shares $4.27 million +7.0%2.8%13.5 $1.08 9/15/20223,710,000 shares $6.01 million +0.3%2.6%12.3 $1.62 8/31/20223,700,000 shares $7.33 million +1.7%2.6%11.6 $1.98 8/15/20223,640,000 shares $8.77 million -2.2%2.5%10.6 $2.41 7/31/20223,720,000 shares $6.88 million -7.9%2.6%9.7 $1.85 7/15/20224,040,000 shares $6.91 million +3.3%2.8%8.4 $1.71 6/30/20223,910,000 shares $6.65 million -4.6%2.7%6.9 $1.70 6/15/20224,100,000 shares $6.60 million -4.7%2.9%7.2 $1.61 5/31/20224,300,000 shares $6.19 million +0.5%3.1%6 $1.44 5/15/20224,280,000 shares $6.03 million -5.5%3.1%4.4 $1.41 4/30/20224,530,000 shares $7.79 million -2.2%3.3%4.5 $1.72 4/15/20224,630,000 shares $8.84 million -0.4%3.4%4.9 $1.91 3/31/20224,650,000 shares $9.58 million -10.2%3.4%4.8 $2.06 3/15/20225,180,000 shares $8.96 million -3.2%3.8%5.1 $1.73 2/28/20225,350,000 shares $13.91 million -2.4%3.9%5.4 $2.60 2/15/20225,480,000 shares $17.37 million +3.0%4.0%7.1 $3.17 1/31/20225,320,000 shares $15.53 million +4.1%3.9%6 $2.92 1/15/20225,110,000 shares $16.86 million +5.6%3.7%5.9 $3.30 12/31/20214,840,000 shares $18.15 million +29.4%3.5%5.8 $3.75 12/15/20213,740,000 shares $13.76 million +10.7%2.7%4.4 $3.68 11/30/20213,380,000 shares $14.03 million +8.3%2.5%3 $4.15 11/15/20213,120,000 shares $13.57 million +5.8%2.3%1.6 $4.35 10/29/20212,950,000 shares $14.96 million -3.9%2.2%1.5 $5.07 10/15/20213,070,000 shares $16.36 million -8.4%2.2%1.6 $5.33 9/30/20213,350,000 shares $17.32 million -44.9%2.4%1.8 $5.17 9/15/20216,080,000 shares $32.83 million +47.9%4.4%3.3 $5.40 8/31/20214,110,000 shares $21.25 million +41.2%3.0%2.5 $5.17 8/13/20212,910,000 shares $11.61 million +8.2%2.1%4 $3.99 7/30/20212,690,000 shares $9.60 million -5.6%2.0%3.3 $3.57 7/15/20212,850,000 shares $10.66 million -5.0%2.1%3.3 $3.74 6/30/20213,000,000 shares $12.78 million -21.7%2.2%3.5 $4.26 6/15/20213,830,000 shares $15.86 million -2.5%2.8%4.2 $4.14 5/28/20213,930,000 shares $19.77 million -1.8%2.9%4.7 $5.03 5/14/20214,000,000 shares $18.24 million -0.7%N/A4.8 $4.56 4/30/20214,030,000 shares $23.29 million +5.0%N/A4.6 $5.78 4/15/20213,840,000 shares $19.35 million +27.2%N/A4.4 $5.04 3/31/20213,020,000 shares $15.25 million +64.1%N/A3.1 $5.05 3/15/20211,840,000 shares $10.08 million -0.5%N/A1.5 $5.48 2/26/20211,850,000 shares $10.99 million +22.5%N/A1.3 $5.94 2/12/20211,510,000 shares $10.01 million +4.9%N/A1 $6.63Blackrock’s Sending THIS Crypto Higher on Purpose (Ad)It's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…YES, I WANT THE #1 CRYPTO NOW 1/29/20211,440,000 shares $7.89 million +8.3%N/A0.9 $5.48 1/15/20211,330,000 shares $8.11 million -64.1%N/A0.8 $6.10 12/31/20203,700,000 shares $20.02 million +31.2%N/A2 $5.41 12/15/20202,820,000 shares $11.56 million No ChangeN/A1.7 $4.10 11/30/20202,820,000 shares $13.85 million -5.1%N/A2.1 $4.91 11/15/20202,970,000 shares $14.82 million -35.0%N/A2.5 $4.99 10/30/20204,570,000 shares $20.70 million -29.0%N/A4.1 $4.53 10/15/20206,440,000 shares $51.20 million +21.1%N/A7 $7.95 9/30/20205,320,000 shares $42.45 million +8.6%N/A7.5 $7.98 9/15/20204,900,000 shares $49.39 million +50.8%N/A6.3 $10.08 8/31/20203,250,000 shares $28.28 million -18.8%N/A4.1 $8.70 8/14/20204,000,000 shares $32.04 million +2.8%N/A1.3 $8.01 7/31/20203,890,000 shares $36.37 million +3.5%N/A1.2 $9.35 7/15/20203,760,000 shares $31.96 million +1.1%N/A1.2 $8.50 6/30/20203,720,000 shares $34.56 million -5.6%N/A1.2 $9.29 6/15/20203,940,000 shares $41.09 million +605.1%N/A1.3 $10.43 5/29/2020558,800 shares $6.19 million +39.4%N/A0.2 $11.07 5/15/2020401,000 shares $1.74 million -45.2%N/A0.7 $4.35 4/30/2020731,400 shares $2.46 million -10.0%N/A1.6 $3.36 4/15/2020812,400 shares $2.68 million +14.7%0.9%1.6 $3.30 3/31/2020708,600 shares $2.44 million +70.5%0.8%0.4 $3.45 3/13/2020415,600 shares $1.25 million -11.4%0.5%1.1 $3.01 2/28/2020468,800 shares $1.32 million -28.2%0.5%0.2 $2.81 2/14/2020653,000 shares $2.00 million +11.8%0.7%0.3 $3.06 1/31/2020584,100 shares $2.05 million -66.4%0.7%0.3 $3.51 1/15/20201,740,000 shares $7.24 million +13.7%2.0%0.9 $4.16 12/31/20191,530,000 shares $6.00 million -35.2%1.7%1 $3.92 ADAP Short Interest - Frequently Asked Questions What is Adaptimmune Therapeutics' current short interest? Short interest is the volume of Adaptimmune Therapeutics shares that have been sold short but have not yet been covered or closed out. As of October 31st, traders have sold 5,350,000 shares of ADAP short. Learn More on Adaptimmune Therapeutics' current short interest. What is a good short interest ratio for Adaptimmune Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. ADAP shares currently have a short interest ratio of 4.0. Learn More on Adaptimmune Therapeutics's short interest ratio. Is Adaptimmune Therapeutics' short interest increasing or decreasing? Adaptimmune Therapeutics saw a decrease in short interest during the month of October. As of October 31st, there was short interest totaling 5,350,000 shares, a decrease of 3.8% from the previous total of 5,560,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Adaptimmune Therapeutics' short interest compare to its competitors? Here is how the short interest of companies in the sector of "medical" compare to Adaptimmune Therapeutics: Cellectis S.A. (0.28%), Precigen, Inc. (10.76%), Fate Therapeutics, Inc. (13.96%), Atara Biotherapeutics, Inc. (16.03%), bluebird bio, Inc. (24.54%), Entrada Therapeutics, Inc. (7.68%), Pharvaris (0.76%), Arbutus Biopharma Co. (3.45%), CorMedix Inc. (10.35%), Tectonic Therapeutic (4.56%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Charter Communications, Inc. ($4.08 billion), AppLovin Co. ($3.18 billion), Paychex, Inc. ($2.64 billion), Nu Holdings Ltd. ($2.54 billion), International Paper ($2.46 billion), Cencora, Inc. ($2.27 billion), Moderna, Inc. ($1.87 billion), SoFi Technologies, Inc. ($1.81 billion), Lululemon Athletica Inc. ($1.75 billion), and Onsemi ($1.71 billion). View all of the most shorted stocks. What does it mean to sell short Adaptimmune Therapeutics stock? Short selling ADAP is an investing strategy that aims to generate trading profit from Adaptimmune Therapeutics as its price is falling. ADAP shares are trading down $0.01 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Adaptimmune Therapeutics? A short squeeze for Adaptimmune Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of ADAP, which in turn drives the price of the stock up even further. How often is Adaptimmune Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ADAP, twice per month. The most recent reporting period available is October, 31 2024. More Short Interest Resources from MarketBeat Related Companies PGEN Short Interest Data CLLS Short Interest Data FATE Short Interest Data ATRA Short Interest Data BLUE Short Interest Data MBIO Short Interest Data TRDA Short Interest Data ABUS Short Interest Data DNTH Short Interest Data CRMD Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:ADAP) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adaptimmune Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Adaptimmune Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
